Can I buy cyclosporine without a prescription in the EU?

No. Cyclosporine is a prescription-only medicine across all EU member states. You must obtain a valid prescription from a licensed physician. It is not available over-the-counter in any form, including eye drops, because it requires medical supervision and blood level monitoring.

Is cyclosporine the same across all EU countries?

The active ingredient and strength are identical, but brand names differ by country. Sandimmun is the original innovator brand; Neoral is a microemulsion formulation; generic versions are also available. All must be EMA-authorised or approved by the national authority of each member state.

What happens if I try to import cyclosporine from outside the EU?

Personal importation of cyclosporine manufactured outside the EU is illegal. Customs authorities may seize the product. Only medicines authorised by the EMA or equivalent bodies in EEA/mutual recognition countries are legally permitted.

Has cyclosporine's EU approval changed recently?

No major changes to its legal status. The EMA's PRAC continuously reviews safety data, but cyclosporine remains authorised across all member states. Any significant regulatory actions (restrictions, label updates) would be publicly announced on the EMA website.

Why is cyclosporine prescription-only when it's been used for 40 years?

Because it's a potent immunosuppressant with serious long-term risks, including kidney damage, infection, and cancer. Blood level monitoring is essential to balance efficacy and safety—this requires prescriber oversight and is why it remains strictly controlled.

Cyclosporine Legal Status in the EU: Approved & Regulated

Cyclosporine is a fully authorised pharmaceutical in the European Union, regulated by the European Medicines Agency (EMA) under the centralised procedure. It's a prescription-only medicine used to prevent organ transplant rejection, treat severe autoimmune conditions like psoriasis and rheumatoid arthritis, and manage chronic dry eye disease. Unlike research compounds, cyclosporine has decades of clinical safety data and is manufactured to strict quality standards. EU patients can access it legally through licensed pharmacies with a doctor's prescription.

Cyclosporine's EU Regulatory Status

Cyclosporine holds EMA authorisation in the European Union—the gold standard for pharmaceutical approval. This means it has undergone rigorous assessment for safety, efficacy, and quality by the EMA's Committee for Medicinal Products for Human Use (CHMP). It is classified as a prescription-only medicine and is not available over-the-counter.

The EMA maintains a central register of all authorised medicines. Cyclosporine appears under multiple brand names across EU member states, including Sandimmun (the original innovator brand), Neoral, and generic formulations. Each brand is subject to the same regulatory oversight and manufacturing standards.

Regulatory History in Europe

Cyclosporine was first approved in Europe in the early 1980s, shortly after its introduction in the United States. Its authorisation represented a paradigm shift in transplant medicine—one-year kidney graft survival rates jumped from approximately 50% to over 80% following its introduction, making it one of the most transformative drugs in medical history.

The compound underwent the centralised procedure, which is mandatory for certain categories of medicines, including immunosuppressants. This procedure ensures a single assessment across all EU member states, rather than requiring separate approvals in each country. Once authorised, cyclosporine became available simultaneously across Europe.

Over the past four decades, cyclosporine has accumulated more than 1,000 clinical trials globally, with extensive European data supporting its use in transplantation, dermatology, rheumatology, and ophthalmology. The regulatory file has been continuously updated with post-marketing surveillance data, adverse event reports, and new formulation studies.

Current Legal Classification

Prescription-only medicine (POM). Cyclosporine cannot be purchased without a valid prescription from a licensed physician in any EU member state. It is not sold in pharmacies to the public without medical oversight.

The reason is straightforward: cyclosporine is a potent immunosuppressant that requires careful dose individualisation and monitoring. Long-term use carries significant risks—nephrotoxicity (kidney damage), hypertension, increased infection risk, and elevated cancer susceptibility are well-documented consequences of sustained immune suppression. Blood level monitoring using trough concentrations is standard clinical practice to optimise efficacy while minimising toxicity. Additionally, cyclosporine interacts with numerous other medications, particularly CYP3A4 inhibitors and inducers, making prescriber oversight essential.

Available Formulations in the EU

Cyclosporine is available in several licensed formulations across Europe:

Oral: Capsules and liquid solutions (e.g., Sandimmun, Neoral). Neoral, a microemulsion formulation, offers improved bioavailability and more predictable blood levels compared to older formulations.

Parenteral: Intravenous injection for hospitalised patients or those unable to take oral medication.

Topical: Eye drops (Restasis, Cequa) for severe dry eye disease. These are prescription-only in the EU, though some countries have different OTC availability rules.

Generic cyclosporine is also available in most EU member states at significantly lower cost than branded versions, provided it is bioequivalent to the reference product.

Manufacturing & Quality Standards

All cyclosporine products sold legally in the EU must be manufactured in compliance with European Pharmacopoeia (Ph. Eur.) standards and EU Good Manufacturing Practice (GMP) guidelines. The EMA conducts regular inspections of manufacturing facilities. This ensures consistent purity, potency, and absence of contaminants—a level of quality assurance that is not guaranteed for compounds obtained outside regulated channels.

What Patients & Prescribers Should Know

For patients: If your doctor prescribes cyclosporine, you are receiving a fully authorised, regulated medicine with decades of safety data. Your prescription is legal and covered by your national health insurance or paid through your pharmacy. Compliance with blood level monitoring and regular check-ups is critical—this is not negotiable, as it directly impacts safety.

For prescribers: Cyclosporine is listed in the therapeutic guidelines of all major European medical societies. Dosing, monitoring protocols, and contraindications are well-established. The Summary of Product Characteristics (SmPC) for each brand provides the legally binding prescribing information. Any brand used must have current EMA authorisation.

Importation into the EU: Cyclosporine manufactured outside the EU cannot be legally imported for personal use, even if purchased in another country. Only products authorised by the EMA or equivalent authorities in countries with mutual recognition agreements (e.g., EEA member states) are permitted.

Enforcement & Post-Marketing Surveillance

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) continuously monitors safety reports for all authorised cyclosporine products. Any new safety signals trigger regulatory action—dose restrictions, label updates, or in rare cases, suspension of authorisation.

National competent authorities (e.g., the UK's MHRA, Germany's BfArM, France's ANSM) also maintain pharmacovigilance systems and inspect pharmacies to ensure only authorised medicines are dispensed.

Comparison to Other Immunosuppressants

Cyclosporine shares EU authorisation with tacrolimus, mycophenolate, and azathioprine, all of which are prescription-only and used in transplantation or autoimmune disease. Tacrolimus has largely superseded cyclosporine as the primary calcineurin inhibitor in organ transplantation, but cyclosporine remains preferred in specific contexts, particularly dermatology and dry eye disease.

Both cyclosporine and its alternative agents are far more heavily regulated than research compounds, which lack regulatory approval and carry undefined safety profiles.

Key Regulatory Documents

EU regulatory information is publicly available:

EMA Product Database: Search by brand name or generic name to find the authorised product information, approved indication, and current status.
Summary of Product Characteristics (SmPC): The legal prescribing information for each brand, including dosing, contraindications, and adverse effects.
Patient Information Leaflet (PIL): Consumer-friendly summary of what the medicine is, how to use it, and what to watch for.

All documents are available in the language of each EU member state.

Summary

Cyclosporine is unambiguously legal in the EU—it is a fully authorised pharmaceutical with robust regulatory oversight, extensive clinical evidence, and decades of real-world safety data. It is available by prescription only, manufactured to strict EU standards, and continuously monitored for safety. Patients and prescribers can be confident in its legal status and pharmaceutical quality.

Cyclosporine Legal Status in the EU: What You Need to Know